Table 2 Patient’s characteristics according to radiation dose to internal mammary lymph node
From: Optimal radiotherapy for patients with internal mammary lymph node metastasis from breast cancer
Characteristics | Number of patients (%) | p-value | ||
|---|---|---|---|---|
50–63.5 Gy 1)(n = 35) | 63.6–70.4 Gy 1)(n = 49) | |||
Age | ≤ 40 years | 15 (42.9%) | 23 (46.9%) | 0.825 |
> 40 years | 20 (57.1%) | 26 (53.1%) | ||
Histologic grade | 1–2 | 23 (71.9%) | 22 (51.2%) | 0.096 |
3 | 9 (28.1%) | 21 (48.8%) | ||
Subtypes | Non-TNBC | 22 (62.9%) | 32 (65.3%) | 0.822 |
TNBC | 13 (37.1%) | 17 (34.7%) | ||
cT stages | 1–2 | 19 (54.3%) | 28 (57.1%) | 0.827 |
3–4 | 16 (45.7%) | 21 (42.9%) | ||
cN stages | 2b or 3b | 26 (74.3%) | 37 (75.5%) | 1.000 |
3c | 9 (25.7%) | 12 (24.5%) | ||
FNABx for IMN | (−) or unknown | 20 (57.1%) | 24 (49.0%) | 0.511 |
(+) | 15 (42.9%) | 25 (51.0%) | ||
Extent of the IMN | Single ICS | 13 (37.1%) | 24 (49.0%) | 0.373 |
Multiple ICS | 22 (62.9%) | 25 (51.0%) | ||
IMN long diameter | < 1.0 cm | 20 (57.1%) | 22 (44.9%) | 0.376 |
≥ 1.0 cm | 15 (42.9%) | 27 (55.1%) | ||
Neoadjuvant chemotherapy | Not done | 9 (25.7%) | 9 (18.4%) | 0.433 |
Done | 26 (74.3%) | 40 (81.6%) | ||
Primary surgery | BCS | 22 (62.9%) | 18 (36.7%) | 0.026 |
Mastectomy | 13 (37.1%) | 31 (63.3%) | ||
Axillary surgery | ALND | 30 (85.7%) | 44 (89.8%) | 0.735 |
SLNB | 5 (14.3%) | 5 (10.2%) | ||